# Kimberly-Clark Corporation (KMB)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-13  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/KMB/primer

## Business Model

---
ticker: KMB
step: 01
generated: 2026-05-12
source: quick-research
---

### Kimberly-Clark Corporation (KMB) — Business Overview

#### Business Description
Kimberly-Clark is a global consumer products company that manufactures and markets personal care, consumer tissue, and professional hygiene products. Founded in 1872 and headquartered in Irving, Texas, the company holds No. 1 or No. 2 market positions in approximately 70 countries. In 2024, KMB launched its "Powering Care" multi-year transformation strategy, simplifying its portfolio and restructuring around three core segments while targeting meaningful margin expansion and higher-quality organic growth.

#### Revenue Model
KMB earns revenue from branded consumer product sales through retail channels (mass, drug, grocery, club stores) and professional channels (commercial distributors). The business is characterized by high repeat purchase rates, stable demand regardless of economic conditions, and pricing power from dominant brand positions. In 2025, KMB completed a joint venture with Suzano (Brazilian pulp company), contributing its International Family Care and Professional businesses into a 49%-owned JV — this restructured KMB's revenue base from ~$20B to ~$17B while improving the margin profile of retained operations.

#### Products & Services
- **Personal Care** — Huggies diapers, Pull-Ups, GoodNites training pants, Kotex feminine care, Poise/Depend adult incontinence
- **Consumer Tissue** — Kleenex facial tissue, Scott bath tissue, Cottonelle, Viva paper towels, Andrex (UK)
- **Professional** — WypAll wipers, Kleenex/Scott commercial tissue; served through Suzano JV post-2025
- **International Brands** — Intimus, Plenitud, Sweety, Softex (emerging markets personal care)

#### Customer Base & Go-to-Market
KMB sells primarily through mass retail (Walmart, Target, Costco), drug chains, grocery stores, and e-commerce. Professional products go through distribution. Consumer segments skew toward households with young children (Huggies) and older adults (Poise/Depend). Emerging markets (Latin America, Southeast Asia) are a growth priority, driven by rising middle-class demand for premium personal care products.

#### Competitive Position
KMB competes directly with Procter & Gamble (Pampers, Charmin, Bounty) in most categories. Despite this heavyweight rivalry, KMB has maintained strong positions through brand loyalty, continuous product innovation, and pricing discipline. The "Powering Care" transformation focuses on winning in premium segments and innovation-led volume gains, moving away from commodity/private-label price battles. The Suzano JV enables KMB to reduce exposure to lower-margin tissue manufacturing while retaining the branded upside.

#### Key Facts
- Founded: 1872
- Headquarters: Irving, Texas
- Employees: ~40,000 (post-JV)
- Exchange: NYSE
- Sector / Industry: Consumer Staples / Household Products
- Market Cap: ~$40–45B (approximate, 2025–2026)

## Financial Snapshot

---
ticker: KMB
step: 04
generated: 2026-05-12
source: quick-research
---

### Kimberly-Clark Corporation (KMB) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | ~$20.2B | ~$20.2B | ~$20.1B | ~0% |
| Gross Margin | ~33% | ~34.4% | ~35.8% | +140bps |
| Operating Margin | ~14% | ~15% | ~16% | |
| Net Income | ~$2.0B | ~$2.6B | ~$2.6B | ~0% |
| EPS (adjusted diluted) | ~$6.00 | $6.57 | $7.30 | +11% |

*Note: FY2025 revenue ~$17.2B reflects the Suzano JV contribution of International Family Care and Professional businesses. Adjusted EPS continues double-digit growth in 2025.*

#### Cash Flow & Balance Sheet (FY2024)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$3.2B |
| Free Cash Flow | $2.51B |
| Cash & Equivalents | ~$0.6B |
| Total Debt | ~$8.0B |

#### Key Ratios (approximate)
- P/E: ~20–22x (adj.) | EV/EBITDA: ~14x | Dividend Yield: ~4%
- Revenue Growth (FY2024 organic): +3.2% | Gross Margin: ~35.8%

#### Growth Profile
KMB's revenue growth has been modest in absolute terms due to FX headwinds and divestitures, but organic growth of 3%+ driven by pricing and volume gains is a positive trend. The strategic focus is on margin expansion: KMB targets 40% gross margin and 18–20% operating margin by end of decade (from current ~35.8%/~16%), implying significant earnings power increase without needing volume acceleration. Adjusted EPS has grown double-digits in 2023 and 2024, funded by operational efficiencies, premiumization, and cost savings.

#### Forward Estimates
- **FY2026**: Organic sales growth guidance of ~2%+ (deceleration from prior years); continued adjusted EPS double-digit growth; gross margin expansion ongoing
- **Margin target**: 40% gross margin and 18–20% operating margin by end of decade — each 100bps of gross margin expansion = ~$170M in gross profit on ~$17B base

## Recent Catalysts

---
ticker: KMB
step: 12
generated: 2026-05-12
source: quick-research
---

### Kimberly-Clark Corporation (KMB) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Margin Expansion to 40% Gross / 18-20% Operating — a Multi-Year Earnings Compounding Story** — KMB has laid out one of the clearest margin expansion roadmaps in consumer staples: from ~35.8% gross margin today to 40%+ by end of decade, and operating margin from ~16% to 18–20%. The Powering Care transformation (launched 2024) is already delivering: seven consecutive quarters of volume-plus-mix gains through Q3 2025, with gross margin up 140bps in FY2024. If the company executes on this roadmap, EPS could compound at 10–12% annually even with modest revenue growth — a rare defensive compounder story in a challenging macro environment.

2. **Suzano JV Simplification + Capital Release** — By contributing its International Family Care and Professional businesses into the 49%-owned Suzano JV, KMB shed lower-margin operations, simplified its business, and freed significant balance sheet capacity. The final regulatory approval (mid-2026) triggers cash flow that can be used for debt reduction or accelerated buybacks. The retained business (North American personal care, premium brands) has structurally higher margins than what was contributed, making the post-JV KMB a cleaner, more profitable company even at lower revenue.

3. **Emerging Markets Premium Upgrade Cycle** — KMB's Huggies and Kotex franchises are positioned to benefit from decades of demographic tailwinds in Latin America, Southeast Asia, and Africa, where rising incomes drive a predictable shift from cloth to disposable diapers and from basic to premium personal care. KMB already holds No. 1 or No. 2 positions in approximately 70 countries, with brand awareness and distribution infrastructure already in place. As income levels rise, per-capita spend on KMB products increases significantly — a structural growth driver independent of near-term economic cycles.

#### Bear Case Risks

1. **Private Label Competition Eroding Market Share** — KMB has experienced a ~30bps year-over-year decline in global market share, reflecting competitive pressure from private label products in North America and Europe. Retailers (particularly Walmart and Amazon) have aggressively grown their own-brand diaper, tissue, and wipes offerings, often at 20–30% price discounts to KMB's brands. In an inflationary/value-seeking consumer environment, trade-down to private label is a persistent structural headwind that pricing power alone cannot fully offset — and KMB exiting private-label diaper manufacturing in the US removes one offset.

2. **Tariff Headwinds + FX Exposure** — Management identified a $300M gross tariff headwind in 2025, primarily from US-China tariffs affecting supply chains and raw material sourcing. While mitigation actions reduced the net impact, tariff policy uncertainty was described as a "downside risk" to full-year guidance. Additionally, KMB's ~40% international revenue creates meaningful FX exposure — a strong dollar consistently creates a multi-hundred-million-dollar translational headwind, even when local businesses perform well. Organic growth of 3% can easily be wiped out by FX at current rate levels.

3. **Transformation Execution Risk + Consumer Demand Deceleration** — The "Powering Care" transformation involves restructuring the organization, divesting/JV-ing major business units, and shifting the entire growth model from price-led to volume-plus-mix-led — all simultaneously. Organic sales growth has already decelerated from mid-single-digits to ~2% in Q1 2026 as the transformation progresses. If volume recovery stalls, KMB's margin expansion plan requires pricing discipline that consumers may resist. Bears characterize the restructured revenue base, two major deals in flight, and commodity cost pressure as making this a "value trap" — defensively valued but with limited near-term earnings acceleration.

#### Upcoming Events
- **Suzano JV Final Approval (~mid-2026)**: Regulatory sign-off triggers cash/proceeds — key capital allocation decision
- **Q2 2026 Earnings (~July 2026)**: Volume/organic growth trajectory and gross margin progress vs. 40% target
- **Transformation Milestones**: Progress toward 40% gross margin; management provides quarterly updates on "Powering Care" KPIs
- **Commodity and Tariff Updates**: Pulp, polypropylene, and other raw material cost trends directly drive gross margin

#### Analyst Sentiment
Generally Hold/Buy split — bulls like the margin expansion story and defensive dividend yield (~4%); bears question execution and organic growth deceleration. Stock has declined ~33% from its 2022 highs as the transformation created near-term earnings noise. Dividend is well-covered (~50% payout ratio on adjusted EPS) and has been raised for 50+ consecutive years (Dividend King status), providing a yield-driven support level.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/kmb
- Full research API: GET /api/v1/research/KMB/memo
- Coverage universe: /stocks